Budax Bio Announces Pricing of $10.0 Million Public Offering – QNT Press Release

[ad_1]

MALVERN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, announced the pricing of its previously announced underwritten public offering of 3,508,772 shares of common stock (or common stock equivalents), together with warrants to purchase up to an aggregate of 3,508,772 shares of common stock (the “Offering”). Each share of common stock (or common stock equivalent) is being sold together with one warrant to purchase one share of common stock at a combined public offering price of $2.85 per share of common stock and accompanying warrant, less the underwriting discounts and commissions. The warrants have an exercise price of $3.25 per share, are exercisable immediately, and will expire five years following the date of issuance. The Offering is expected to close on or about March 1, 2022 , subject to the satisfaction of customary closing conditions.

HC Wainwright & Co. is acting as the sole book running manager for the Offering.

In addition, the Company has granted the underwriter an option to purchase up to an additional 526,315 shares of common stock and/or warrants to purchase up to an additional 526,315 shares of common stock at the public offering price, less the underwriting discounts and commissions.

The gross proceeds from the Offering to the Company, before deducting underwriting discounts and commissions and other Offering expenses and excluding any proceeds that may be received upon exercise of the warrants to purchase shares of common stock and the underwriter’s option to purchase additional shares …

Full story available on Benzinga.com

[ad_2]

Source link